This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. DESCRIPTION (provided by applicant): Columbia University Medical Center's (CUMC) CTSA and Irving Institute for Clinical and Translational Research (IICTR), using the expertise and commitment of faculty in 10 Key Resources have made outstanding progress toward the goal of transforming the culture of clinical and translational (C/T) research at CUMC. Examples include: novel projects using interdisciplinary approaches;a novel, 2-phase inter- disciplinary pilot award program that has already captured several NIH grants;a Website for all service request that also has a faculty directory that facilitates collaborative research;5 hours of free consultation to more than 600 investigators leading to 33 NIH grants and 106 publications;collaboration among several CUMC regulatory groups that has significantly improved contracting, IRB time-to-approval, and ethics education/consultation services;successful launch of satellites research facilities in ICUs and EDs resulting in 50 new investigators conducting 30 new protocols;opening of the Columbia Community Partnership for Health center, one-half mile from CUMC. as a home for community-based organizations and community- based participatory research;launching of a new Master's degree in POR, a novel one year certificate curriculum within existing T32 programs, and an outstanding KL2 program with 9 scholars already capturing independent funding;and transformation of the """"""""old"""""""" GCRC core laboratory into a campus-wide biomarkers core serving T1, T2 and T3 investigators. Throughout, our Tracking and Evaluation Group has provided critical assistance regarding future direction. Most importantly, we have validated the concept of the CTSA and are changing the culture of research at CUMC. In the next 4 years, with institutional support of nearly $4 million yearly, we will build upon this foundation and (1) Expand the resources and infrastructure that we have developed for T2 and T3 clinical researchers;(2) Capitalize on CUMC's outstanding T1 discovery research community by integrating existing resources and investigators even more closely into our CTSA. (3) Improve the health of our community by working with the NYPH ambulatory care network and community based organizations to develop platforms for comparative effectiveness research.

Public Health Relevance

(provided by applicant): The Clinical and Translational Science Award (CTSA) allow Columbia University to support novel programs whose goal is to speed the translation of scientific discoveries made in the laboratory into new therapies. The CTSA will ensure that these new therapies are accepted by practicing physicians and community members so that we can begin to significantly improve the health of our community and nation.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
2UL1RR024156-06
Application #
8365050
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Project Start
2011-07-01
Project End
2012-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
6
Fiscal Year
2011
Total Cost
$4,082,709
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Zyablitskaya, Mariya; Munteanu, E Laura; Nagasaki, Takayuki et al. (2018) Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking (TXL) for Myopia. J Vis Exp :
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Alcalay, R N; Wolf, P; Levy, O A et al. (2018) Alpha galactosidase A activity in Parkinson's disease. Neurobiol Dis 112:85-90
Liu, Chia-Ying; Parikh, Megha; Bluemke, David A et al. (2018) Pulmonary artery stiffness in chronic obstructive pulmonary disease (COPD) and emphysema: The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study. J Magn Reson Imaging 47:262-271
Floyd, J S; Sitlani, C M; Avery, C L et al. (2018) Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. Pharmacogenomics J 18:127-135
Kulminski, Alexander M; Huang, Jian; Loika, Yury et al. (2018) Strong impact of natural-selection-free heterogeneity in genetics of age-related phenotypes. Aging (Albany NY) 10:492-514
Seyerle, A A; Sitlani, C M; Noordam, R et al. (2018) Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology. Pharmacogenomics J 18:215-226
Klitzman, Robert (2018) Gatekeepers for infertility treatment? Views of ART providers concerning referrals by non-ART providers. Reprod Biomed Soc Online 5:17-30
Cullaro, Giuseppe; Pisa, Joseph F; Brown Jr, Robert S et al. (2018) Early Postoperative Neutrophil Gelatinase-Associated Lipocalin Predicts the Development of Chronic Kidney Disease After Liver Transplantation. Transplantation 102:809-815
Rapuano, Patrick B; Scanameo, Alexandra H; Amponin, Daeryl E et al. (2018) Antimicrobial Studies Using the Therapeutic Tissue Cross-Linking Agent, Sodium Hydroxymethylglycinate: Implication for Treating Infectious Keratitis. Invest Ophthalmol Vis Sci 59:332-337

Showing the most recent 10 out of 1009 publications